ECTRIMS Preview: Ocrevus Success Brings Rivals Crowding In
The congress will highlight competition in anti-CD20 and other novel multiple sclerosis drug classes
You may also be interested in...
Satralizumab will be boosted by convenience and MS portfolio in increasingly competitive field.
The market opportunity in the EU for Alexion’s Soliris has increased following European Commission approval of the additional indication, NMOSD. The EU indications for Bristol-Myers Squibb’s Empliciti have been extended to include use with pomalidomide and dexamethasone in a triplet combination for relapsed and refractory multiple myeloma.
Gilead and Arcus believe their ‘Fc silent’ TIGIT inhibitor candidate could be best in class, but analysts think only outstanding results in lung cancer will sway investor sentiment.